In partnership with Liberating Technologies, Inc., a College Park Company, RxFunction will create a system using Walkasinsneuroprosthetic technology to carry out advanced balance and gait training for those utilizing artificial limbs.
FREMONT, CA: RxFunction, Inc. has been chosen by the Defense Health Agency to receive a Small Business Innovation Research (SBIR) Direct Phase II contract in order to fund the development that will include Walkasins sensory neuroprosthetic technology into artificial limbs for better rehabilitation of gait and a balance for active-duty military members, veterans, and the civilians with lower limb trauma and loss.
The project will be conducted in collaboration with Liberating Technologies, Inc. (LTI), the research arm of College Park Industries, now part of Ossur Group, a global leader in non-invasive orthopedics. The grant is anticipated to be more than one million dollars.
“I am thrilled that we were able to get this competitive Department of Defense contract in collaboration with the excellent research team at LTI,” said Dr. Lars Oddsson, Principal Investigator, CTO of RxFunction, and co-inventor of the Walkasins technology. “It is a wonderful opportunity to be able to combine our technology, experience and expertise with theirs to develop a new rehabilitation tool that can help improve gait and balance function for those with lower limb loss.”
Dr. Todd Farrell, Director of Research at LTI, additionally says, “We are incredibly excited to have the opportunity to continue our collaboration with the team at RxFunction. This project aligns with our companys strategic goals of developing novel technologies to improve the quality of life of individuals with limb difference. I believe that the synergistic nature of the technologies that each company is bringing to the project will allow for the development and deployment of an effective rehabilitation tool for the Warfighter, Veteran, and civilian populations.”
The loss of balance and the associated falls are a substantial problem for active-duty military members, civilians, and veterans with lower limb trauma and limb loss. Therapists at present lack readily available tools to be used in the clinic for advanced balance and gait training to lessen the fall risk and increase performance.
The future commercial applications would extend the technology into a prosthesis to provide remote patient monitoring capabilities with therapy on an ongoing basis.
RxFunction CEO, Tom Morizio said, “It’s exciting to see this next development coming out of our strong and extensive IP portfolio. This project can help open a market to serve a new population of patients in need, and is in line with our longer-term plans to expand this technology into other applications and new neuromuscular disease indications, building on our work in peripheral neuropathy.”